Vaginal News and Research

RSS

Perrigo files ANDA for butoconazole nitrate vaginal cream

Perrigo Company announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for butoconazole nitrate vaginal cream, 2% and that is has notified KV Pharmaceutical Company, the owner of the New Drug Application as well as FemmePharma, the listed owner of the patent, of its ANDA filing. KV is a licensee under the patent. Perrigo believes it is first-to-file on this product.

31 Jul 2010

Cytori Therapeutics receives European approval for Celution System

Cytori Therapeutics received expanded European approval (CE Mark) for its Celution System, a medical device that extracts and separates stem and regenerative cells from a patient's own fat tissue. The new indications include key medical applications such as breast reconstruction, repair of soft tissue defects, as well as the facilitation of healing certain types of wounds, such as those resulting from Crohn's disease. This broadens Cytori's ability to offer the Celution System to patients and hospitals and further supports the company's efforts to gain treatment reimbursement.

28 Jul 2010

Obesity linked to rising womb cancer in women: Report

According to a new report from the Charity Cancer Research (CCR) in Britain, the number of women with womb cancer or uterine cancer is on the rise and obesity may be a clue to such rise.

26 Jul 2010

China Sky One Medical receives SFDA approval for producing Ciclopirox Olamine Vaginal Suppositories

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company in the People's Republic of China, today announced that the Company has obtained approval from the State Food and Drug Administration in China for the production of Ciclopirox Olamine Vaginal Suppositories.

23 Jul 2010

New era of scientific innovation to drive novel ways of treating, preventing HIV

The unwillingness of the global AIDS community to accept the status quo is fuelling a new era of scientific innovation to drive novel ways of treating and preventing HIV, organizers of the XVIII International AIDS Conference taking place in Vienna, Austria said today. And, with millions of lives dependent on expanding access to antiretroviral treatment to all those clinically in need, researchers and clinicians are partnering in new ways to find the most effective and efficient methods to deliver treatment and strengthen health systems.

22 Jul 2010

Smoking cessation effectively alter subgingival microbiome in patients on periodontal therapy: Study

Patients with chronic gum disease who quit smoking in addition to undergoing nonsurgical therapy not only demonstrated a lower abundance of harmful oral pathogens, but also an increase in health-associated bacteria. The researchers from The Ohio State University, Columbus Ohio, and Newcastle University, United Kingdom report their findings in the July 2010 issue of the Journal of Clinical Microbiology.

22 Jul 2010

Prototype ring with sensors helps to detect, prevent preterm labor

The birth of a baby is usually a joyous event, but when a child is born too early, worrisome complications can occur, including serious health problems for the baby and steep medical bills for the family. To address this, Johns Hopkins graduate students and their faculty adviser have invented a new system to pick up very early signs that a woman is going into labor too soon.

22 Jul 2010

Study marks significant milestone for microbicide research field, HIV prevention

Today we congratulate the Centre for the AIDS Programme of Research in South Africa and the people of South Africa on the positive findings from the CAPRISA 004 microbicide study, which marks a significant milestone both for the microbicide research field and HIV prevention as a whole.

22 Jul 2010

Womb cancer is the fourth most common cancer among UK women: Research

Womb cancer cases are highest ever for over three decades.The number of women diagnosed with womb cancer is at its highest for over 30 years according to new figures published today by Cancer Research UK which show more than 7,530 people now develop the disease each year in the UK.

22 Jul 2010

Vaginal birth after previous C-section may be a safe option say doctors

According to new practice guidelines revealed for obstetricians by the American College of Obstetricians and Gynecologists this Wednesday, a vaginal birth after a Caesarean section (VBAC) or maybe even after two C-sections can be a safe and appropriate choice.

21 Jul 2010

HIV and Human Rights March to prevent new infections, provide treatment for people with HIV

The call for human rights as a fundamental component of efforts to prevent new infections and provide treatment for people living with HIV pervaded the XVIII International AIDS Conference today as delegates and local residents prepared for the HIV and Human Rights March through the streets of Vienna this evening. Conference participants are giving voice to the conference theme of Rights Here, Right Now through a number of plenary presentations, sessions, and Global Village and Youth Programme activities.

21 Jul 2010

AIDS 2010: Study finds microbicide containing HIV drug lowers infection risk in women by 39%

A microbicide gel containing Gilead's HIV drug tenofovir used by women before and after sex has been shown to reduce their risk of HIV infection by nearly 40%, according to a study unveiled at the International AIDS Conference-AIDS 2010, Reuters reports

21 Jul 2010

First Edition: July 20, 2010

Today's headlines reflect more analysis and debate regarding continuing health reform implementation efforts.

20 Jul 2010

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Researchers who conducted a study testing a vaginal microbicide with an antiretroviral (ARV) drug called tenofovir found its use before and after sex was significantly more protective against HIV infection than a placebo gel among women at high risk of HIV. Results of the study, known as CAPRISA 004, are to be reported at the International AIDS Conference (AIDS 2010) in Vienna and published online by the journal Science.

20 Jul 2010

Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention

Results of an advanced clinical trial of an antiretroviral-based microbicide candidate are being announced at the International AIDS Conference in Vienna, Austria. The CAPRISA 004 trial, which tested the safety and effectiveness of 1% tenofovir gel among nearly 900 women at two sites in South Africa, found that using the gel before and after sex provided moderate protection against sexually transmitted HIV.

20 Jul 2010

AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection

"This is a historic day for HIV prevention research. The CAPRISA 004 results are the first clinical evidence that a microbicide gel can help to prevent sexual transmission of HIV infection," said AVAC Executive Director Mitchell Warren, reacting to the results of the landmark microbicide trial presented today at the International AIDS Conference in Vienna.

20 Jul 2010

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

Researchers have achieved an important scientific breakthrough in the fight against HIV and genital herpes with a vaginal gel that significantly reduces a woman's risk of being infected with these viruses. The results of the ground-breaking safety and effectiveness study of an antiretroviral microbicide gel study were reported today by the Centre for the AIDS Programme of Research in South Africa at the XVIII International AIDS Conference in Vienna, Austria.

20 Jul 2010

New microbicide gel reduces woman's risk of being infected with HIV, genital herpes

Today at the XVIII International AIDS Conference in Vienna, Austria, members of the International Rectal Microbicide Advocates (IRMA) and thousands of other HIV advocates and scientists cheered a long-awaited, much anticipated success in the quest for new HIV prevention technologies. Researchers announced that a vaginal gel has been shown to significantly reduce a woman's risk of being infected with HIV and genital herpes

20 Jul 2010

Infants in African countries receive minimum help to reduce risk of mother-to-child HIV transmission: Study

Only about half of infants born to HIV-infected mothers in some African countries receive a minimum preventive dose of the drug nevirapine to help reduce the risk of mother-to-child HIV transmission, according to a study in the July 21 issue of JAMA, a theme issue on HIV/AIDS.

20 Jul 2010

Starpharma gets FDA nod to start phase 2 bacterial vaginosis study for VivaGel

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced it had received clearance from the US Food and Drug Administration (FDA) to commence a phase 2 study to investigate VivaGel® for the treatment of bacterial vaginosis (BV).

15 Jul 2010

Vaginal News and Research

Perrigo files ANDA for butoconazole nitrate vaginal cream

Cytori Therapeutics receives European approval for Celution System

Obesity linked to rising womb cancer in women: Report

China Sky One Medical receives SFDA approval for producing Ciclopirox Olamine Vaginal Suppositories

New era of scientific innovation to drive novel ways of treating, preventing HIV

Smoking cessation effectively alter subgingival microbiome in patients on periodontal therapy: Study

Prototype ring with sensors helps to detect, prevent preterm labor

Study marks significant milestone for microbicide research field, HIV prevention

Womb cancer is the fourth most common cancer among UK women: Research

Vaginal birth after previous C-section may be a safe option say doctors

HIV and Human Rights March to prevent new infections, provide treatment for people with HIV

AIDS 2010: Study finds microbicide containing HIV drug lowers infection risk in women by 39%

First Edition: July 20, 2010

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention

AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

New microbicide gel reduces woman's risk of being infected with HIV, genital herpes

Infants in African countries receive minimum help to reduce risk of mother-to-child HIV transmission: Study

Starpharma gets FDA nod to start phase 2 bacterial vaginosis study for VivaGel

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News